AK-AVS™
Novel ECG Application (e.g., Structural Heart Disease)
ResearchActive
Key Facts
Indication
Novel ECG Application (e.g., Structural Heart Disease)
Phase
Research
Status
Active
Company
About AccurKardia
AccurKardia is a private, commercial-stage digital health company developing AI-powered software to unlock deeper insights from ECG data. The company has achieved its first regulatory milestone with the FDA 510(k) clearance of its AccurECG™ interpretation application, positioning it in the cardiovascular diagnostics and remote monitoring market. Its pipeline includes investigational products, AK-AVS™ and AK+ Guard™, aimed at extending ECG analysis to new disease areas, signaling a strategic shift towards establishing the ECG as a broad biomarker. The company is led by a team with blended expertise in cardiology, medical devices, data analytics, and healthcare operations.
View full company profile